IP Verse

Chimeric Antigen Receptor (Car) That Targets Chemokine Receptor Ccr4 And Its Use - EP3515475

The patent EP3515475 was granted to The United States Government Represented BY The Department OF Veterans Affairs on May 1, 2024. The application was originally filed on Sep 20, 2017 under application number EP17778069A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3515475

THE UNITED STATES GOVERNMENT REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
Application Number
EP17778069A
Filing Date
Sep 20, 2017
Status
Granted And Under Opposition
Mar 29, 2024
Grant Date
May 1, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

WEICKMANN & WEICKMANNJan 30, 2025WEICKMANN & WEICKMANN PARTMBBADMISSIBLE

Patent Citations (78) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0090505
DESCRIPTIONEP1866339
DESCRIPTIONEP1947183
DESCRIPTIONFR901228
DESCRIPTIONUS2006121005
DESCRIPTIONUS2010028330
DESCRIPTIONUS2012039906
DESCRIPTIONUS2012114649
DESCRIPTIONUS2012213783
DESCRIPTIONUS2014050708
DESCRIPTIONUS2014271635
DESCRIPTIONUS4458066
DESCRIPTIONUS4722848
DESCRIPTIONUS5593972
DESCRIPTIONUS5643578
DESCRIPTIONUS5817637
DESCRIPTIONUS5858358
DESCRIPTIONUS5880103
DESCRIPTIONUS5883223
DESCRIPTIONUS6111090
DESCRIPTIONUS6352694
DESCRIPTIONUS6534055
DESCRIPTIONUS6692964
DESCRIPTIONUS6797514
DESCRIPTIONUS6867041
DESCRIPTIONUS6887466
DESCRIPTIONUS6905680
DESCRIPTIONUS6905681
DESCRIPTIONUS6905874
DESCRIPTIONUS7025962
DESCRIPTIONUS7067318
DESCRIPTIONUS7144575
DESCRIPTIONUS7172869
DESCRIPTIONUS7175843
DESCRIPTIONUS7232566
DESCRIPTIONUS7618632
DESCRIPTIONUS7812135
DESCRIPTIONUS7943743
DESCRIPTIONUS8008449
DESCRIPTIONUS8354509
DESCRIPTIONUS8388967
DESCRIPTIONUS8586023
DESCRIPTIONUS8591886
DESCRIPTIONUS8609089
DESCRIPTIONWO0103720
DESCRIPTIONWO03064383
DESCRIPTIONWO2005007190
DESCRIPTIONWO2005055808
DESCRIPTIONWO2005115451
DESCRIPTIONWO2006083289
DESCRIPTIONWO2006121168
DESCRIPTIONWO2007005874
DESCRIPTIONWO2007133822
DESCRIPTIONWO2009101611
DESCRIPTIONWO2009114335
DESCRIPTIONWO2010003118
DESCRIPTIONWO2010027827
DESCRIPTIONWO2010077634
DESCRIPTIONWO2011028683
DESCRIPTIONWO2011051726
DESCRIPTIONWO2011066342
DESCRIPTIONWO2011090754
DESCRIPTIONWO2012079000
DESCRIPTIONWO2013039954
DESCRIPTIONWO2013059593
DESCRIPTIONWO2013126712
DESCRIPTIONWO2013126726
DESCRIPTIONWO9920758
DESCRIPTIONWO9940196
INTERNATIONAL-SEARCH-REPORTWO2013166500
INTERNATIONAL-SEARCH-REPORTWO2016100985
OPPOSITIONUS2004043401
OPPOSITIONWO2012079000
OPPOSITIONWO2013123061
OPPOSITIONWO2013166500
OPPOSITIONWO2016014565
OPPOSITIONWO2016100985
OPPOSITIONWO2018057585

Non-Patent Literature (NPL) Citations (5) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- D09: Supplementary Figure 2-
OPPOSITION- Zhiwei Zhang et al, "Modified CAR T cells targeting membrane-proximal epitope of mesothelin enhances the antitumor function against large solid tumor", Cell Death & Disease, (20190701), vol. 10, no. 7, doi:10.1038/s41419-019-1711-1, XP055727451
OPPOSITION- D.-K. Chang et al, "Humanization of an Anti-CCR4 Antibody That Kills Cutaneous T-Cell Lymphoma Cells and Abrogates Suppression by T-Regulatory Cells", Molecular Cancer Therapeutics, American Association for Cancer Research, Inc., (20121101), vol. 11, no. 11, doi:10.1158/1535-7163.MCT-12-0278, ISSN 15357163, pages 2451 - 2461, XP055069589
OPPOSITION- Watanabe Keisuke et al, "Identifying highly active anti-CCR4 CAR T cells for the treatment of T-cell lymphoma", Blood Advances, American Society of Hematology, (20230725), vol. 7, no. 14, doi:10.1182/bloodadvances.2022008327, ISSN 2473-9529, pages 3416 - 3430, XP093259116
OPPOSITION- Urs B. Hagemann et al, "Fully Human Antagonistic Antibodies against CCR4 Potently Inhibit Cell Signaling and Chemotaxis", PLoS ONE, Public Library of Science, vol. 9, no. 7, doi:10.1371/journal.pone.0103776, pages 1 - 22, XP055284593

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents